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Parkinson’s disease (PD), a neurodegenerative disorder, is the second most common neurological illness in United States.
Neurologically, it is characterized by the selective degeneration of a unique population of cells, the nigrostriatal dopamine neurons.
The current treatment is symptomatic and mainly involves replacement of dopamine deficiency.This therapy improves only motor
symptoms of Parkinson’s disease and is associated with a number of adverse effects including dyskinesia. Therefore, there is unmet
need for more comprehensive approach in the management of PD. Cannabis and related compounds have created significant
research interest as a promising therapy in neurodegenerative and movement disorders. In this review we examine the potential
benefits of medical marijuana and related compounds in the treatment of bothmotor and nonmotor symptoms as well as in slowing
the progression of the disease. The potential for cannabis to enhance the quality of life of Parkinson’s patients is explored.
1. Introduction
Marijuana, the crude product (dried flowers, stems, seeds,
and leaves) derived from the cannabis sativa plant, consists
of more than 85 phytocannabinoids [1, 2]. The term phy-
tocannabinoids is used to differentiate these plant-derived
cannabinoids from the synthetic cannabinoids and the struc-
turally different endogenous cannabinoids (endocannabi-
noids). Among the phytocannabinoids, Cannabidiol (CBD)
andΔ9-Tetrahydrocannabinol (Δ9-THC, THC) are themajor
constituents ofmarijuana [3].Δ9-THC is a psychoactive agent
with analgesic and muscle relaxant property [3, 4]. While
CBD is a nonpsychoactive compound and has been shown
to have hypnotic, anxiolytic, antipsychotic, antioxidant, and
neuroprotective effects [5], THC is a partial agonist at the
cannabinoid receptor 1 (CB1) and receptor 2 (CB2). Unlike
Δ9-THC, CBD has antagonistic/inverse agonistic property at
CB1 receptor and appears to modulate Δ9-THC-associated
side effects including anxiety, tachycardia, and hunger [3].
CBD also appears to potentiate the effect of endocannabi-
noids by inhibiting their inactivation, thereby alleviating
psychotic symptom [6].
Despite the placement of marijuana in the schedule 1
category under the US Federal Controlled Substance Act [7]
and the US Federal Government’s continued opposition on
its legalization, 24 states and Washington DC have enacted
laws allowing marijuana to treat certain medical conditions
[8]. The range and types of disease conditions for which
medical marijuana have been approved vary from state to
state. The most common disease conditions approved by the
states include cancer, HIV/AIDS, glaucoma, chronic and/or
severe pain, seizure/epilepsy, cachexia, andmultiple sclerosis.
Moreover, two cannabinoids (dronabinol and nabilone) have
been approved by the FDA for clinical use. The synthetically
produced Δ9-THC, dronabinol (Marinol), is a schedule III
drug, which is indicated in the treatment of chemotherapy-
induced nausea and emesis as well as anorexia associated
with weight loss in AIDS patients. A synthetic cannabinoid,
nabilone (Cesamet), is a schedule II drug that is indicated
for the treatment of nausea and vomiting associated with
cancer chemotherapy. Another cannabinoid, Cannabidiol
(Epidiolex), is in a clinical trial for the treatment of drug-
resistant epilepsy in children [9]. A phytocannabinoid prepa-
ration, nabiximols (Sativex), has been approved for the
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treatment of spasticity due to multiple sclerosis in a number
of countries outside the United States. Nabiximols is an
extract of Cannabis sativa L that consists of mainly THC and
CBD [10, 11].
Although recent studies have provided strong evidence
for the therapeutic benefit of medical marijuana [12–16],
increasing access to cannabis and/or cannabinoids can result
in side effects such as addiction, respiratory illness, and
decline in cognitive processing. Cannabis use has been
indicated as a potential cause, aggravator, or masker of major
psychiatric symptoms, including psychotic, depressive, and
anxiety disorders, particularly in young people [17–19]. Other
negative effects include working memory deficits, reduced
attention and processing speed, anhedonia, abnormal social
behavior, and susceptibility to mood and anxiety disor-
ders [20, 21]. While adult users seem comparatively resis-
tant to cannabis-induced behavioral and brain morphologic
changes, the individuals who start using cannabis during
their early teens can have more severe and more long-lasting
effects [22].
The target of medical marijuana and its constituents
is the endocannabinoid system, which is involved in the
modulation of a number of physiological functions. The
endocannabinoid system includes the endocannabinoids, the
cannabinoid receptors, and the enzymes involved in the
biosynthesis and inactivation of the endocannabinoids [23]
The cannabinoid receptors aremainly expressed in the central
nervous system and the immune system, but they have also
been identified in a number of other parts of the body includ-
ing the cardiovascular system, the peripheral nervous system,
the reproductive system, and the gastrointestinal tract. Due
to its wide distribution and effects on a range of biological
process, the cannabinoid system has become an attractive
target for the development of drugs that can potentially be
used for the treatment of a number of pathological conditions
including mood disorders and movement disorders such as
PD [24]. Components of the endocannabinoid system are
abundant in the striatum and other parts of the basal ganglia
and play a crucial role in modulating dopamine activity and
motor functions [25–27].
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder following Alzheimer’s disease
and the 14th leading cause of death in all age groups in
the United States [28]. The prevalence of PD increases with
age and is shown to be higher in males than females in
some age groups [29]. The number of people with PD is
projected at approximately 9 million by 2030 in the 15 most
populous countries in the world [30, 31]. Neurologically
PD is characterized by the destruction of dopaminergic
cells in the pars compacta region of the substantia nigra
in the midbrain, resulting in dopamine deficiency in the
nerve terminals of the striatum in the forebrain [32]. These
changes cause impairments not just to the motor system
but also to the cognitive and neuropsychological systems
[33]. The nigrostriatal pathway is one of the dopamine
pathways in the brain that regulates movement. The exact
cause for the loss of neuronal cells is unknown, and the trigger
of dopaminergic degeneration seems to be multifactorial
including environmental factors and genetic susceptibilities
[34–36]. Clinically, PD is characterized by resting tremor,
muscle rigidity, bradykinesia, and postural instability [32,
34, 37, 38] and it is also associated with a number of
nonmotor symptoms including depression, anxiety, consti-
pation, orthostatic hypotension, fatigue, and sleep disorders,
as well as, in advanced disease, dementia [39–44]. Although
dopamine deficiency accounts for themajormotor symptoms
of the disease, loss of noradrenergic and serotoninergic nerve
terminals in the limbic system may account for several of the
nonmotor features seen in Parkinson’s disease [45, 46].
Current therapy involves treatment of motor symptoms
of PD through replacement of dopamine deficiency [47].
This includes (1) enhancement of the synthesis of brain
dopamine by administration of levodopa, a dopamine pre-
cursor, (2) direct stimulation of dopamine receptors, (3)
decreasing dopamine catabolism, and (4) stimulation of
dopamine release and inhibition of dopamine reuptake from
presynaptic sites. Another therapy involves restoring the
normal balance of cholinergic and dopaminergic actions on
the basal ganglia using anticholinergic drugs [47–49].
However these drugs treat only motor symptoms of
Parkinson’s disease and are associated with a number of
adverse effects. Long-term use of levodopa, the mainstay
therapy for PD, is associated with motor fluctuations [50]
and levodopa-induced dyskinesia [51–53]. The monoamine
oxidase B (MAO-B) inhibitors (selegiline and rasagiline) as
well as inhibitors of catechol-o-methyltransferase, COMT
(tolcapone and entacapone), are used mostly to reduce the
motor fluctuations associated with levodopa therapy due
to their levodopa-sparing effect [54–59]. Several dopamine
agonists including pramipexole, ropinirole, rotigotine, and
apomorphine are used as monotherapy in early stage of
Parkinson disease or as adjunctive therapy with levodopa
in patients with advanced PD in order to reduce motor
fluctuations [56, 60–64]. In addition to their limited efficacy
on motor symptoms and their adverse effects, drugs that are
currently used for the treatment of PD do not have an effect
on disease progression.Therefore, there is an urgent need for
the development of safer drugs that treat both the motor and
nonmotor symptoms of PD as well as drugs that slow the
progression of the disease.
Medical marijuana has been demonstrated to improve
motor symptoms including tremor, rigidity, and bradykinesia
as well as nonmotor symptoms such as pain and sleep
disorders of PD in observational studies [65]. Survey of
PD patients in Colorado, USA, also indicated the beneficial
effects of marijuana in alleviating nonmotor symptoms of
PD [66]. Cannabidiol (CBD), one of the major constituents
of marijuana, has been shown to be effective in the treat-
ment of psychosis and sleep disorders in PD patients [67–
69]. Another phytocannabinoid, Δ9-tetrahydrocannabivarin
(Δ9-THCV, THCV), was studied in animal disease model
of PD and found to have neuroprotective and symptom-
relieving effects [70]. Therefore, marijuana may provide an
alternative or add-on therapy for Parkinson’s disease. In
addition, Parkinson’s disease has been listed as one of the
disease conditions for which medical marijuana is allowed in
Connecticut, Illinois, Massachusetts, New Hampshire, New
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Mexico, and New York. However, it may also be covered
under chronic illnesses in several other states.
In this review we seek to investigate any scientific evi-
dence that indicates the potential use of marijuana and/or
its components for the treatment of Parkinson’s disease. The
review aims to (i) examine briefly current treatment and
the unmet need of PD therapy, (ii) assess the role of the
cannabinoid system in the modulation of movement and
neuroprotection, (iii) look at the mechanism of action of
marihuana constituents in the modulation of movement and
PD-associated disorders, (iv) assess other beneficial effects of
marihuana that contribute to the amelioration of PD, and (v)
gather scientific evidence on the clinical benefit of marijuana
and/or its constituents in PD patients.
2. Marijuana and Its Influence on
the Endocannabinoid System
Cannabis has been used to treat disease since ancient times.
Marijuana is derived from the Cannabis sativa L. plant. Mar-
ijuana contains the active chemicals known as cannabinoids.
At least 85 cannabinoids have been identified as unique com-
pounds in Cannabis [1]. The therapeutic potential of many
of these ligands still remains largely unexplored prompting a
need for further research. The chemicals responsible for the
medicinal effects of marijuana are D9-Tetrahydrocannabinol
(THC) and Cannabidiol (CBD) [71, 72]. THC is the major
psychoactive ingredient, acting primarily upon the central
nervous system where it affects brain function. CBD is the
major nonpsychoactive ingredient in cannabis and produces
neuroprotective and anti-inflammatory effects [73]. Both
compounds, TCH and CBD, have anticonvulsant properties
[74]. Cannabinoids have also potential to alleviate motor
disorders by reducingmotor impairments and neuron degen-
eration [75]. In addition, cannabinoids have been shown
to be effective in preclinical studies involving excitotoxicity,
oxidative stress, neuroinflammation, and motor complica-
tions associated with PD [76].
Some cannabinoids (endocannabinoids or ECBs) are
found in the body. Initially, ECBswere discovered in the brain
and subsequently in the periphery in humans and animals.
Endocannabinoids are produced by cultured neurons [77],
microglia, and astrocytes [78]. ECBs interact with the endo-
cannabinoid system and aid in regulation of memory, plea-
sure, concentration, thinking, movement and coordination,
sensory and time perception, appetite, and pain [24, 79, 80].
The ECBs activate two guanine nucleotide-binding protein-
(G-protein-) coupled cell membrane receptors, consequently
named the cannabinoid type 1 (CB1) and type 2 (CB2) recep-
tors [81]. CB1 receptors are located primarily in the central
and peripheral neurons andCB2 receptors are predominantly
found in immune cells [82]. CB1 receptors are important
mediators in signaling pathways and have been identified
on both glutamatergic and gamma-aminobutyric (GABA)
neurons [83]. It is believed that one important role of the
neuronal CB1 component is to modulate neurotransmitter
release in amanner thatmaintains homeostasis by preventing
the development of excessive neuronal activity in the central
nervous system [82]. Animal models illustrate that activation
of the CB1 receptor by their endogenous ligands can result in
prominent neuroprotective effects and may prevent epileptic
seizures [84]. Other studies suggest that activation of CB1
receptors offers neuroprotection against dopaminergic lesion
and the development of L-DOPA-induced dyskinesias [85].
CB2 receptors are closely related to CB1 and are mainly
expressed on T cells of the immune system, on macrophages
and B cells, and in hematopoietic cells [86]. They are also
expressed on peripheral nerve terminals where these recep-
tors play a role in antinociception and the relief of pain
[87]. In the brain, CB2 receptors are mainly expressed by
microglial cells, where their role remains unclear [88].
The major identified ECBs are arachidonoyl ethanola-
mide (anandamide, AEA), 2-arachidonoyl glycerol (2-AG),
O-arachidonoyl ethanolamine (virodhamine), and 2-ara-
chidonoyl glyceryl ether (noladin ether) [89]. Both AEA and
2-AG are specific ligands of CB1 and CB2 receptors. Besides
having activity on CB1 and CB2 receptors, AEA also has full
agonistic activity at TRPV1 receptor [90]. AEA is localized
in the brain and periphery [91]. In the brain AEA shows
high distribution in the hippocampus, thalamus, striatum,
and brainstem and to a lesser extent in the cerebral cortex and
cerebellum [92]. Lower concentrations of AEA are found in
human serum, plasma, and cerebrospinal fluid [93]. Similarly,
2-AG is observed in both the brain and periphery, although its
concentration is almost 150 times higher in brain compared
to that of AEA [92, 94, 95]. 2-AGhas greater potency, stability,
and agonistic activity at CB1 and CB2 receptors compared
to that of AEA [96, 97]. Two prominent areas involved in
the control of movement, such as the globus pallidus and the
substantia nigra, contain not only the highest densities of CB1
receptors [88], but also the highest levels of ECBs, especially
AEA [98, 99]. Tissue levels of AEA are regulated by fatty
acid amide hydrolase (FAAH) [100]. It has also been shown
that the basal ganglia contain the precursor of AEA [98, 99],
supporting the theory of in situ synthesis for this compound.
Studies have demonstrated that AEA synthesis is regulated by
dopaminergic D2 receptors in the striatum, suggesting that
the endocannabinoid system acts as an inhibitory feedback
mechanism countering the dopamine-induced facilitation of
motor activity [101].
Marijuana compound THC is CB1 and CB2 receptor
partial agonist [82]. Due to the structural similarity of natural
cannabinoid THC to the endogenous cannabinoid AEA,
many therapeutic advantages of THC have been identified,
such as lowering ocular pressure, inhibiting smooth muscle
contractions, and increasing appetite [102]. When smoked,
THC is rapidly absorbed from the lungs into the bloodstream
and has an effect on the cannabinoid receptors. The central
nervous system and specific areas of the brain contain the
highest concentration of cannabinoid receptors. Therefore,
cannabis or THC administration can create an overexcitation
of the system that results in altered perceptions, pleasure, and
mood [103].
Unlike THC, CBD has little affinity for CB1 and CB2
receptors but acts as an indirect antagonist of cannabinoid
agonists. While this should cause CBD to reduce the effects
of THC, it may potentiate THC’s effects by increasing CB1
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receptor density or through another CB1-related mechanism
[73]. CBD is also an inverse agonist of CB2 receptors. CBD
can counteract some of the functional consequences of CB1
activation in the brain, possibly by indirect enhancement
of adenosine A1 receptors activity through equilibrative
nucleoside transporter (ENT) inhibition [73]. CBD helps to
augment some of THC’s beneficial effects, as it reduces the
psychoactivity of THC, enhances its tolerability, and widens
THC’s therapeutic window [104].
Other cannabinoids can also contribute to the cannabis
medicinal effects. Studies in experimental models and hu-
mans have suggested anti-inflammatory, neuroprotective, anx-
iolytic, and antipsychotic properties of chemicals extracted
from marijuana [6, 15, 82, 105, 106].
3. Cannabinoids and Parkinson’s Disease
3.1. Changes in the Cannabinoid System in Parkinson’s Disease.
Recent data from several studies indicate the important
role of the endocannabinoid system in Parkinson’s disease.
The components of the endocannabinoid system are highly
expressed in the neural circuit of basal ganglia, which is
part of a complex neuronal system. This neuronal system
coordinates activities from different cortical regions that
directly or indirectly participate in the control of movement
[107, 108]. In the basal ganglia, the endocannabinoid system
bidirectionally interacts with dopaminergic, glutamatergic,
and GABAergic signaling systems [109]. Endocannabinoids
play a dominant role in controlling transmission at synapses
between cortical and striatal neurons, in mediating the
induction of a particular form of synaptic plasticity, and in
modulating basal ganglia activity and motor functions [110].
The progressive loss of dopaminergic neurons that occurs
in PD leads to lower striatal levels of dopamine. These low
levels of dopamine result in the alteration of the equilibrium
between the direct and the indirect basal ganglia pathways
and ECB signaling [111].
The cannabinoid signaling system mentioned above
experiences a biphasic pattern of changes during the pro-
gression of PD [112]. Early and presymptomatic PD stages,
characterized by neuronal malfunction with little evidence
of neuronal death, are associated with desensitization/down-
regulation of CB1 receptors and aggravation of various
cytotoxic insults such as excitotoxicity, oxidative stress, and
glial activation [113]. However, intermediate and advanced
stages of PD, characterized by a deep nigral degeneration
and manifestation of major Parkinsonian symptoms, are
associated with upregulatory responses of CB1 receptors and
the endocannabinoid ligands [113]. This could explain the
potential of CB1 receptor ligands in alleviating common PD
symptoms.
In the brain, CB1 receptors are expressed by GABAergic
neurons innervating the external and internal segments of the
globus pallidus and the substantia nigra [114–116]. CB1 recep-
tors are also present in the corticostriatal glutamatergic ter-
minals and in the excitatory projections from the subthalamic
nucleus to the internal segment of the globus pallidus and the
substantia nigra [114–116].Within the striatum, CB1 receptors
are expressed in parvalbumin immune-reactive interneurons,
cholinergic interneurons, and nitric oxide synthase-positive
neurons [117, 118]. Animal models of Parkinson’s disease
show an increase in the density of CB1 receptors, levels of
endogenous ligands, and CB1 receptor binding in the basal
ganglia [119–122]. Endogenous cannabinoids activate CB1
receptors on presynaptic axons and reduce neurotransmitter
and glutamate release, working as retrograde synaptic mes-
sengers released from postsynaptic neurons [123]. Similarly,
activation of CB1 receptors inhibits both glutamate release
from substantia nigra afferents and GABA release from
striatal afferents. At the same time, activation of presynaptic
CB1 receptors in the external segments of the globus pallidus
can increase local GABA levels by reducing GABA reuptake
from striatal afferents to the nucleus and decrease GABA
release from striatal afferents of the substantia nigra [114,
116, 118]. Based on these evidences, it is thought that the
function of the basal ganglia neuronal system is controlled by
ECB. The presence of endocannabinoid systems in different
neural structures and their interaction with dopaminergic,
glutamatergic, and GABAergic neurotransmitter signaling
systems make the components of endocannabinoid system
ideal targets for a novel nondopaminergic treatment of PD.
Endocannabinoid signaling is also bidirectionally linked
to dopaminergic signaling within the basal ganglia [118].
The CB1, D1, and D2 dopamine receptors are localized
in the striatum [114, 115]. In animal models, CB1 and D2
dopamine receptors share a common pool of G proteins,
suggesting the link of their signal transduction mechanisms
[124, 125]. In addition, D2 receptor stimulation resulted in
release of ECBs in the striatum [101]. However, stimulation
of CB1 receptors completely inhibited D1-dopamine receptor
mediated activation of adenylyl cyclase and decreased GABA
release from striatal afferents of dopaminergic neurons of the
substantia nigra resulting in an increased firing of these cells
[114–116].
Another receptor involved in control of movement is
transient receptor potential vanilloid type 1 (TRPV1), which
is expressed in sensory neurons and basal ganglia circuitry
of dopaminergic neurons [126, 127]. TRPV1 receptors are
molecular integrators of nociceptive stimuli activated by
endovanilloids [128]. TRPV1 also interacts with ECB. In
particular, anandamide is one of the major endogenous acti-
vators of TRPV1 [129–131]. Studies have revealed that motor
behavior can be suppressed by the activation of vanilloid
receptors [98, 99], suggesting that TRPV1 receptors might
play a role in the control of motor function.
3.2. Preclinical Data on the Endocannabinoid System as a
Target for Parkinson’s Disease Therapy. The association of
cannabinoids with regulation of motor functions is well
established [132–135].The effect of the cannabinoids onmotor
activity depends on the impact of the endocannabinoid
system on the dopaminergic, glutamatergic, and GABAergic
signaling systems throughout the basal ganglia [112, 136].
The high density of cannabinoid, dopamine, and vanilloid-
like receptors coupled with ECBs within the basal ganglia
and cerebellum suggests a potential therapeutic role for the
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cannabinoids in the control of voluntary movement and
in movement disorders such as Parkinson’s disease [98, 99,
121, 137]. Additional indications of an important role of the
endocannabinoid system in the control of movement involve
an inhibitory action of cannabinoids through fine tuning of
various classical neurotransmitters activity [138], prominent
changes in transmission of ECBs in the basal ganglia [139],
and alteration of the CB1 binding as well as CB1 availability
in the substantia nigra [85, 112, 119, 120, 140, 141]. These data
support the idea that cannabinoid- based compounds act on
vital pathways of endocannabinoid transmission and there-
fore might be of therapeutic interest due to their potential to
diminish motor symptoms in extrapyramidal disorders such
as Parkinson’s disease [27, 76, 142].
Research with cannabinoid agonists and antagonists
demonstrates that the cannabinoids can modulate motor
activity and produce alterations in corresponding molecular
correlates [129, 143–145]. It has been widely reported that
synthetic, plant-derived, or endogenous cannabinoid ago-
nists exert a powerful motor inhibition in laboratory species
[129, 144, 146–149]. This hypokinetic effect was shown to be
mediated by the activation of CB1 receptors in neurons of
the basal ganglia circuitry [88, 137, 141, 150–152]. Stimulation
of the CB1 receptor by a synthetic cannabinoid HU-210
decreased spontaneous glutamatergic activity and reduced
the rotations induced by levodopa/carbidopa by 34% in PD
rats [153, 154]. Administration of CB1 receptor agonists THC
and two synthetic cannabinoidsWIN 55,212-2 and CP 55,940
increased extracellular dopamine concentrations in rats [152,
155, 156]. WIN 55,212-2 and CP 55,940 also weakened
contralateral rotations induced by a selective D1/D5 receptor
partial agonist SKF38393 without developing catalepsy in PD
rats [148]. In a gender study THC produced an increase in
tyrosine hydroxylase activity in parkin-null male mice (a
model of early stages of PD) and caused a motor inhibition
that was significantly greater compared to wild-type animals
[122]. Treatment with THC inhibited motor activity and
produced catalepsy in rats [109, 144, 146, 147] and caused
antinociception and ring immobility in mice [157]. In other
studies THC diminished the motor inhibition caused by 6-
hydroxydopamine [70] and potentiated the hypokinetic effect
of reserpine in rats more than 20-fold [135]. However, in
a primate model of Parkinson’s disease THC did not affect
locomotor activity but increased bradykinesia [125].
Administration of WIN 55,212-2 increased stimulation
of GTP𝛾S binding in the caudate nucleus, putamen, globus
pallidus, and substantia nigra of marmosets, indicating an
effective activation of CB1 signaling mechanisms [119, 120].
WIN 55,212-2 produced a dose-dependent reduction of the
spontaneous motor activity and catalepsy in mutant Syrian
hamsters, increased antidystonic efficacy of benzodiazepines
[158], and significantly reduced the antikinetic effects of
quinpirole in the reserpine-treated rats [159]. Treatment
with WIN 55,212-2 also reduced levodopa-induced dyskine-
sias, attenuated axial, limb, and severe orolingual abnormal
involuntary movements in 6-hyroxydopamine- (6-OHDA-)
lesioned rats [160–163]. An endogenous cannabinoid agonist
oleoylethanolamide (OAE) produced reduction in dyskinetic
contralateral rotations correlatedwith reduction ofmolecular
associates of L-DOPA-induced dyskinesia: reduced FosB
striatal overexpression and phosphoacetylation of hystone
3 [164]. Another synthetic agonist levonantradol decreased
general and locomotor activity and increased bradykinesia
in a primate model of Parkinson’s disease [125]. Nabilone,
a synthetic cannabinoid agonist, coadministered with lev-
odopa significantly decreased total dyskinesia comparedwith
levodopa alone treatment and increased the duration of
antiparkinsonian action of levodopa by 76% in PD mar-
mosets [165, 166].
Cannabinoid agonist anandamide (AEA) and its syn-
thetic analog methanandamide increased the extracellular
dopamine levels in the nucleus accumbens shell of rats
by the activation of the mesolimbic dopaminergic system
[167]. This dopamine increase was inhibited by the cannabi-
noid CB1 receptor antagonist rimonabant [167]. However,
recent discoveries indicate that AEA is also able to acti-
vate vanilloid VR(1) receptors and that the activation of
these receptors might also be responsible for changes in
nigrostriatal dopaminergic activity and anandamide-induced
hypokinesia [168–170]. AEA produced a tonic facilitation of
glutamate release in the substantia nigra via stimulation of
VR1 receptors, indicating the involvement of this receptor in
motor and cognitive functions of the dopaminergic system
[171]. Preclinical data have shown that AEA decreased the
activity of nigrostriatal dopaminergic neurons and produced
hypokinesia that was completely reversed by an antagonist
of vanilloid-like receptors, capsazepine [129]. Additional
studies have demonstrated that AEA inhibited ambulation
and stereotypic behavior, increased inactivity, and occluded
the effects of an agonist of vanilloid VR1 receptors, livanil,
on locomotion in mice, suggesting a common mechanism
of action for the two compounds [170]. Treatment with
anandamide lowered motor activity with the maximal inhi-
bition by approximately 85% and produced hypothermia and
analgesia inmice, increased the inactivity time, andmarkedly
decreased the ambulation and the frequency of spontaneous
non-ambulatory activities in rats [146, 147, 172, 173]. More-
over, AEAproduced a decrease in spontaneousmotor activity
in laboratory animals similar to the reported actions of THC
[129, 145, 153, 170]. The hypokinetic actions of AEA were
boosted by coadministration with a selective inhibitor of
endocannabinoid uptake N-(3-furylmethyl) eicosa-5,8,11,14-
tetraenamide, UCM707 [174].
Tissue concentrations of endocannabinoids are impor-
tant for producing motor effects. Levels and activities of
AEA and 2-AG can be manipulated by inhibition of FAAH
enzyme, the action of which is reduced in experimental
models of PD [153, 175]. Animal studies have shown that the
FAAH enzyme inhibitor [3-(3-carbamoylphenyl) phenyl] N-
cyclohexylcarbamate (URB597) magnified and prolonged a
rapid, brief dopamine increase that was produced by AEA
[167]. Additional studies have confirmed that FAAH inhibi-
tion remarkably increases AEA tissue levels but reduces 2-
AG levels [176, 177]. To determine whether FAAH inhibition
has beneficial impact on PD symptoms the effect of the
FAAH inhibitor, URB597, was studied in MPTP- lesioned
marmosets. Treatment with URB597 increased plasma levels
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of AEA, did not modify the antiparkinsonian actions of L-
DOPA, and reduced the magnitude of hyperactivity to levels
equivalent to those seen in normal animals [178]. In PD
mice URB597 prevented induced motor impairment [179].
Moreover, other FAAH inhibitors, JNJ1661010 and TCF2, also
have anticataleptic properties [179]. These results reveal that
FAAH inhibition may represent a new strategy for treatment
of PD.
Overall, these results indicate that endogenous or exoge-
nous cannabinoid agonists activate the dopaminergic system
and play a very important role in modulation of motor
behavior [180]. In addition to the effects on movement
activity, cannabinoid agonists have demonstrated neuropro-
tective properties, suggesting that the cannabinoids have a
promising pharmacological profile for not only improving
Parkinsonian symptoms but also delaying PD progression
[70, 85, 181–183].
The CB1 receptor antagonists can also influence move-
ment syndromes of Parkinson’s disease suggesting that mod-
ulation of the CB1 signaling system might be valuable in
treatment of motor disorders. In a study with PD rats rimon-
abant (SR141716A), a selective antagonist of CB1 receptors has
shown the potential to act as an antihypokinetic agent by
enhancing glutamate release from excitatory afferents to the
striatum [184]. Moreover, SR141716A prevented the effects of
THC on dopamine release [156, 167] and also increased the
locomotor activity in mice and rats preexposed to THC [170,
185]. SR141716A produced a 71% increase in motor activity
in MPTP-lesioned marmosets with LID [136]. Coadminis-
tration of SR141716A with levodopa resulted in significantly
less dyskinesia than administration of levodopa alone [136,
160]. SR141716A also reversed effect of the cannabinoid
agonist WIN 55,212-2 and increased the locomotor activity
in 6-OHDA-lesioned animals [159, 163]. Coadministration of
SR141716A with a selective D2/D3 receptor agonist quinpirole
reduced levels of AEA and 2AG by sevenfold in the globus
pallidus, boosted the locomotive effects of quinpirole, and
produced restoration of locomotion in animal models of
Parkinson’s disease [98, 99, 101, 136, 186]. In parkin-null
mice SR141716A produced a decrease in tyrosine hydroxylase
activity in the caudate–putamen and as result formed a
hyperkinetic response [122]. However, SR141716A did not
alleviate the motor deficits in a primate model of Parkinson’s
disease [125].
Another CB1 receptor antagonist AM251 and SR141716A
produced antiparkinsonian effects in rats with very severe
nigral degeneration (>95% cell loss) [187]. Local adminis-
tration of these antagonists into denervated striatum, globus
pallidus, and subthalamic nucleus reducedmotor asymmetry
in Parkinsonian rats [187, 188], which was inhibited by CB1
receptor agonist AM404 [187]. Another CB1 antagonist CE-
178253 produced a 30% increase in motor behavior responses
to L-DOPA in MPTP-treated rhesus monkeys but did not
modify levodopa-induced dyskinesias [189]. THCV caused
changes in glutamatergic transmission and attenuated the
motor inhibition in PD rats [70]. Overall, these findings
suggest that cannabinoid CB1 antagonists might be thera-
peutically effective in the control of Parkinson’s disease and
levodopa-induced dyskinesia [114, 190].
The activation of CB2 receptors might also contribute to
some extent to the potential of cannabinoids in PD [191].
THCV, which is not only a CB1 antagonist but also a CB2 par-
tial agonist, reduced the loss of tyrosine hydroxylase-positive
neurons in the substantia nigra with preservation of these
neurons in CB2 receptor-deficient mice [70]. CBD has also
reduced the loss of tyrosine hydroxylase-positive neurons in
the substantia nigra of PD rats. Both compounds, THCV and
CBD, have acted via neuroprotective and antioxidant mech-
anisms [70, 182, 191]. CBD has also demonstrated significant
effects in preclinical models of neurodegenerative disorders
in combination with other cannabinoids [15, 70, 192]. CB2
receptor agonists display a promising pharmacological profile
for delaying disease progression.
The cannabinoid pharmacologicmanipulation represents
a promising therapy to alleviate movement disorders and
levodopa-induced dyskinesias. Thus, CB1 antagonists appear
to have antiparkinsonian effects, while cannabinoid receptor
agonists may be useful in the treatment of motor complica-
tions in Parkinson’s disease.
3.3. Effect of Cannabinoids on Patients with Movement Dis-
orders. Cannabis and related compounds have created sig-
nificant research interest as a promising therapy in neurode-
generative and movement disorders. The successful use of
tincture of Cannabis indica in treating PD was first described
in Europe by Gowers [193]. Despite the lack of controlled
studies, there is evidence that cannabinoids are of therapeutic
value in the treatment of tics in Tourette syndrome, some
forms of tremor and dystonia, chorea inHuntington’s disease,
the reduction of levodopa-induced dyskinesia in Parkinson’s
disease, and Parkinsonian syndromes [194–201].
A study with smoked cannabis queried 339 PD patients
indicated that marijuana produced significant improvement
of general PD symptoms in 46% of the patients; 31 % of them
reported improvement in resting tremor, 38% reported relief
from rigidity, 45% defined reduced bradykinesia, and 14%
of the patients reported alleviated dyskinesias [202]. High
urine concentration (>50 ng/ml) of the THC primary active
metabolite, 11-HO-THC, was associated with relief from PD
symptoms [202]. The dose and frequency of the cannabis
administrations were important in relieving PD symptoms.
Smoked cannabis also produced a statistically significant
improvement in tremor, rigidity, and bradykinesia as well
as improvement in sleep and pain scores in 22 PD patients
[65]. In another study, smoked cannabis was responsible for
a significant improvement in the mean total motor Unified
Parkinson’s Disease Rating Scale (UPDRS) score, tremor,
rigidity, and bradykinesia in 17 patients with PD [203]. One
dose of smoked marijuana provided symptoms relief for up
to 3 hours [203]. Moreover, both studies reported significant
improvement of nonmotor symptoms of PD, such as pain
and sleep [65, 203]. However, smoked marijuana did not
reduce Parkinsonian symptoms in 5 patients with idiopathic
Parkinson’s disease and severe tremor [204]. A clinical trial
in 19 PD and 6 patients with levodopa-induced dyskinesia
demonstrated that oral cannabis extract was ineffective for
alleviating parkinsonism or dyskinesia [205].
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Few studies have evaluated the effects of CBD on PD
symptoms. In a pilot study CBD lowered total UPDRS
scores and significantly reduced psychotic symptoms in 6 PD
patients with psychosis [67]. In another study CBD admin-
istration produced no improvement in measures of motor
and general symptoms in 21 PD patients [68, 69]. However,
the group treated with CBD had significantly different mean
total scores in the Parkinson’s Disease Questionnaire, 39
compared to the placebo group [68, 69]. Oral CBD improved
dyskinesia by up to 30% without a significant worsening
of the parkinsonism in PD patients [206]. CBD withdrawal
caused severe generalized dystonia [206].
Clinical studies have been conducted to evaluate the
effect of a synthetic cannabinoid nabilone. Oral nabilone
significantly reduced dyskinesia without aggravating parkin-
sonism in seven PD patients with severe L-DOPA-induced
dyskinesia [207]. In another study, nabilone produced a 22%
reduction in levodopa-induced dyskinesia in PD patients
[208]. Nabilone showed efficacy not only against LID but
also against bradykinesia in PD patients [209]. Some other
cannabinoid related compounds such as CE178253, OEA, and
HU-210 have also been reported to be efficacious against
L-DOPA-induced dyskinesia and bradykinesia in PD [199,
209]. However, SR 141716 did not improve Parkinsonian
motor disability in PDpatients [210].TheAmericanAcademy
of Neurology (AAN) review deemed marijuana “probably
ineffective” for treating L-DOPA-induced dyskinesia [211].
These conflicting results indicate the need for more research
in this area.
Several clinical studies have been performed to evaluate
the effect of marijuana on dystonia. Inhaled cannabis has
provided a marked reduction in dystonia and complete pain
relief in patients with right hemiplegic painful dystonia.
Moreover, the patients have been able to completely dis-
continue opioid use [212]. Smoked cannabis also improved
idiopathic dystonia and generalized dystonia due to Wilson’s
disease [213, 214]. In a preliminary study, administration of
CBD resulted in a 50% improvement in spasm severity and
frequency in a patient with blepharospasm-oromandibular
dystonia [215] and amelioration of the dystonic movements
within 2-3 hours in patients with dystonic movement dis-
orders [201]. CBD also improved dystonia by 20–50% in
dystonic patients and stopped tremor and hypokinesia in
2 patients with Parkinson’s disease [200]. Another cannabis
compound, THC, produced a reduction of abnormal move-
ment patterns in a 14-year-old girl withmarked dystonia [216]
and decreased intensity of myoclonic movements in a 13-
year-old boy with athetosis and myoclonic movements [216].
In contrast to these findings, one study found no significant
reduction in dystonia following treatment with nabilone [165,
166].
Studies have looked at the potential benefits of medical
marijuana and cannabinoids for the treatment of Hunt-
ington’s disease (HD). Nabilone versus placebo showed a
treatment difference of 0.86 for total motor score; 1.68 for
chorea; 3.57 for Unified Huntington’s Disease Rating Scale
(UHDRS) cognition; 4.01 for UHDRS behavior; and 6.43
for the neuropsychiatric inventory in HD patients [217].
However, in previous study nabilone was found to increase
choreatic movements in patients with HD [197, 198]. AAN
guideline examining the efficacy of marijuana for treating
chorea in HD stated nabilone can be used for modest
decreases in HD chorea [218]. Available data regarding the
effect of CBD on HD symptoms are inconsistent. CBD
produced improvement (20–40%) in the choreic movements
in HD patients [219]. However, a latter study did not confirm
the earlier finding [220]. A comparison of the effects of
CBD and placebo on chorea severity in neuroleptic-free
HD patients indicated no significant or clinically important
differences [220].
Few studies have indicated that marijuana and THC can
reduce tics and associated behavioral disorders in patients
with Tourette’s syndrome (TS) [221]. Cannabis inhalations
produced a significant amelioration of TS symptoms [222].
Followingmarijuana administration 82% of TS patients (𝑁 =
64) reported a reduction, or complete remission of motor
and vocal tics, and an amelioration of premonitory urges
and obsessive-compulsive symptoms (OCB) [199]. Smoked
marijuana also eliminated TS symptoms in one case study
[223]. Administration of THC to a boy with TS improved
tics and enhanced short-interval intracortical inhibition and
the prolongation of the cortical silent period [224]. TCH
significantly reduced tics and improve driving ability in a
Tourette’s patient [225]. Treatment with THC lowered the
mean C1 specific over nonspecific binding ratio (𝑉󸀠󸀠
3
) from
0.30 to 0.25 in six TS patients, although the difference was not
significant. However 𝑉󸀠󸀠
3
clearly declined in a patient with a
marked clinical response [226]. To date, there have been only
two controlled trials that investigated the effect of THC on
TS [194], both of which reported a significant improvement
of tics and OCB after THC administration [195, 196].
Considering the relevance of these data, the need for alter-
native treatments for PD motor and nonmotor symptoms,
medical marijuana, or related compoundsmay provide a new
approach to the treatment of Parkinson’s disease.
4. Beneficial Effects of Cannabinoids in the
Amelioration of Nonmotor Symptoms and
Progression of Parkinson’s Disease
4.1. Neuroprotective Actions of Cannabinoids. Cannabinoids
have been shown to have neuroprotective effect due to their
antioxidative, anti-inflammatory actions and their ability to
suppress exitotoxicity. Plant-derived cannabinoids such as
THC and CBD can provide neuroprotection against the in
vivo and in vitro toxicity of 6-hydroxydopamine and this was
thought to be due to their antioxidative property or modula-
tion of glial cell function or a combination of both [182]. Stud-
ies found that CBD was able to recover 6-hydroxydopamine-
induced dopamine depletion and also induced upregulation
of Cu, Zn-superoxide dismutase, which is a key enzyme in
endogenous defense against oxidative stress [70, 191, 227].
The reported data suggest that CBD also diminishes the
increase in nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase expression and decreases the markers
of oxidative stress, inflammation, and cell death in the
kidneys [228]. Another study has also emphasized a role for
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superoxide anion produced by microglial NADPH oxidase
in augmenting the demise of dopaminergic neurons in the
PD brain [229]. The mechanism by which CBD acts to
reduce NADPH oxidase expression and inhibit oxidative
injury within the PD brain has yet to be confirmed but
it seems to act through mechanisms independent of CB1
or CB2 receptors [76]. However, data obtained from recent
studies have hinted towards a direct relationship between
the CB1 receptor and mitochondrial functions in the brain
[230]. The phenolic ring moieties in cannabinoids display
antioxidant activity guarding against glutamate-induced neu-
rotoxicity in a cellular model [231]. CBD produced reduc-
tion of hydroperoxide-induced oxidative damage and was
more protective against glutamate neurotoxicity compared to
ascorbate and a-tocopherol, indicating that CBD is a potent
antioxidant [232]. Taken together, these discoveries support
the hypothesis that treatment with cannabinoids having
antioxidant effects may modulate mitochondrial reactive
oxygen species production [233] in the PD brain.
Inflammation has been shown to be a crucial patho-
logical factor responsible for the demise of dopaminergic
neurons in PD [234–236]. Glial cells appear to play a key
role in neuroinflammation, since higher levels of activated
microglia are reported in the substantia nigra of patients
with PD compared to brains of control subjects [237, 238].
Cannabinoids demonstrate anti-inflammatory activities by
suppressing toxic cytokine release and microglia activation
[181–183]. Increased CB2 receptor expression in nigral cells
and stimulation of these receptors protect dopaminergic
neurons from microglia-induced inflammation and regulate
neuronal survival [70]. The cannabinoids are known to be
able to activate the CB2 receptor, which mediate the anti-
inflammatory effects of the compounds and preserve cells
from excessive apoptosis. Recent evidence substantiates that
some cannabinoids may attenuate the neuroinflammation
associatedwith PD [191, 239–241]. Several studies showed that
CBD has anti-inflammatory properties [242–246] and can
produce beneficial effect in acute inflammation and chronic
neuropathic states [5, 247, 248]. THC demonstrates anti-
inflammatory effect via activation of the CB1 receptor [249–
251]. In addition, cannabinoids provide anti-inflammation
effect by reducing the vasoconstriction and restoring blood
supply to the injured area [252]. All these data support
that cannabinoids are potentially effective compounds for
the treatment of neuroinflammatory conditions, including
neurodegenerative diseases like PD.
Marijuana may prevent brain damage by protecting
against neuronal injury.There are a fewmechanisms bywhich
cannabinoids provide neuroprotection. One of the mech-
anisms involves an induction/upregulation of cannabinoid
CB2 receptors, mainly in reactivemicroglia, and regulates the
influence of these glial cells on homeostasis of surrounding
neurons [253]. In combination with the increased antitoxic
effects observed in cell cultures containing glia, this sug-
gests that immunomodulation produced by CB2 receptor
activation may play a primary role in the neuroprotective
properties of cannabinoids [182]. Anothermechanismof neu-
roprotection is activation of CB1 receptors. Loss of dopamin-
ergic neurons and greater degree of motor impairment in
CB1 knockout mice have been reported [85]. Cannabinoids
activating the CB1 receptor are antiexcitotoxic due to sup-
pression of glutamatergic activity with a subsequent decrease
in calcium ion influx and eventual nitric oxide production
[254–256]. Sativex-like combination of phytocannabinoids
has been demonstrated to produce neuroprotective effect
via interaction with both CB1 and CB2 receptors [134, 257].
In addition, THC reduced the loss of tyrosine hydroxylase-
positive neurons in the substantia nigra [70] and exhibited
neuroprotective effect by activation of the PPAR𝛾 receptors
[258]. Overall, these data suggest that cannabinoids are
neuroprotective in acute and chronic neurodegeneration and
can delay or even stop progressive degeneration of brain
dopaminergic system, a process that cannot be prevented
currently.
4.2. Analgesic Effect of Cannabinoids. Pain is a relevant and
often underestimated nonmotor symptom of PD [259, 260].
Pain affects more that 50% of people with this disorder
and can cause extreme physical, psychological, and social
disorders and worsen Parkinsonian disability [261, 262].
Different treatment options are used to treat PD pain [262–
265]. However, these medications have significant side effects
and do not provide universal efficacy [264, 265]. Cannabis
is well known as a pain-relieving plant. The cannabinoid
receptors in the central and peripheral nervous systems have
been shown to modulate pain perception [266, 267].
Several clinical studies have been performed to inves-
tigate the effect of marijuana or cannabinoids on pain.
Smoked cannabis significantly reduced neuropathic pain
intensity as well as significantly improved mood disturbance,
physical disability, and quality of life in HIV-patients [268].
Cannabis was effective at ameliorating neuropathic pain in
patients with central and peripheral neuropathic pain [269].
Inhaled cannabis significantly reduced pain intensity (34%)
compared to placebo in a clinical trial of painful distal sym-
metric polyneuropathy (DSPN) [270]. Whole plant extracts
of Cannabis sativa produced statistically significant improve-
ments on the mean pain severity score [271]. Cannabis-based
medicine significantly decreased chronic pain intensity as
well as sleep disturbance in multiple sclerosis patients [272,
273]. Oromucosal nabiximols (1 : 1 combination of the THC
and CBD) produced a reduction in pain intensity scores in
patients with neuropathic pain [274].
These findings are consistent with other discoveries
supporting the efficacy of cannabis in relieving pain. The
analgesic effect of cannabinoids has been reviewed [75, 211,
275–281].The review of the literature suggests that marijuana
and/or cannabinoids may be efficacious for pain relieving in
various disease states including PD.
4.3. Antidepressant Effect of Cannabinoids. Depression is
one of the common nonmotor symptoms of PD and the
estimated rate varies widely, with an average prevalence of up
to 50%. [282–284]. Despite its association with poor health
outcomes and quality of life, depression in PD patients is
underdiagnosed and undertreated [285–287]. Studies have
indicated that the endocannabinoid system is involved in
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the regulation of mood and emotional behavior, and the
loss or blockade of the endocannabinoid signaling system
results in depressive symptoms [288]. For example, the CB1
receptor antagonist rimonabant has been shown to induce
symptoms of anxiety and depression [289–291]. In addition,
polymorphism of the gene that encodes the CB1 receptor
has been associated with depression in PD [292]. In animal
models, low level of THC produced antidepressant activity
and increased serotogenic activity via activation of the CB1
receptor [293]. Animal studies have also shown that inhibi-
tion of hydrolysis of the endocannabinoid anandamide exerts
antidepressive effect [294] and resulted in an increased sero-
tonergic andnoradrenergic neuronal activity in themidbrain.
Currently available antidepressant drugs act via increasing
serotonin and/or noradrenaline levels.These, andmany other
studies, indicate that the cannabinoid system is a potential
target for the development of novel antidepressant drugs.
Epidemiological studies have demonstrated that people who
used cannabis daily or weekly exhibit less depressed mood
and more positive effect than nonusers of cannabis [295].
Other studies have shown an association between heavy
cannabis use and depressive symptoms. However, it is not
clear whether the increased depressive symptoms are due
to cannabis use or other factors that increased the risk of
both depression and heavy use of cannabis [296]. Therefore,
moderate use of cannabis in PD patients may help alleviate
depressive symptoms and improve quality of life.
4.4. Effect of Cannabinoids on Sleep Disorders. Sleep disor-
ders are common in PD patients and negatively affect the
quality of life. The reported prevalence ranges from 25%
to 98% and this wide variation could be due to differ-
ences in study design and diagnostic tools used [297]. The
causes of the sleep disturbances in PD are multifactorial
and include neurodegeneration and the medications used
to treat motor symptoms of PD [298]. Various sleep disor-
ders including rapid eye movement sleep behavior disorder,
insomnia, sleep fragmentation, excessive daytime sleepiness,
restless legs syndrome, and obstructive sleep apnea have been
described in PD patients [299, 300]. Cannabidiol, the major
nonpsychotic component of marijuana, has been reported to
improve rapid eye movement sleep behavior disorder in PD
patients [68, 69]. Marijuana has also been shown to improve
nonmotor symptoms of PD including sleep [65]. In clinical
trials involving 2000 patients with various pain conditions,
nabiximols has been demonstrated to improve subjective
sleep parameters [301]. Thus, marijuana could be used to
enhance the quality of life of PD patients by alleviating sleep
disorders and pain.
5. Summary
Cannabis and related compounds have recently been studied
as promising therapeutic agents in treatment of neurode-
generative and movement disorders including Parkinson’s
disease. In this review we have examined the potential
benefits of medical marijuana and cannabinoids in the
treatment of both motor and nonmotor symptoms as well as
in slowing the progression of the disease. We have looked
into any scientific evidence that indicates the potential use
of marijuana and/or related compounds for the treatment of
PD. Current treatments of PD provide only relief of motor
symptoms and are associated with adverse effects such as
dyskinesia. In addition, these therapies do not slow the
progression of the disease. Therefore, there is an urgent need
for safer drugs that can treat both motor and nonmotor
symptoms of PD as well as drugs that slow the progression
of the disease.
In spite of the placement of marijuana in schedule 1
category under the US Federal Controlled Substance Act, 24
states andWashingtonDChave enacted laws allowing the use
of marijuana to treat a range of medical conditions. Parkin-
son’s disease has been listed as one of the disease conditions
for whichmedical marijuana is allowed in a number of states.
Research studies have provided evidence for the potential
effectiveness of medical marijuana and its components in the
treatment of PD as cannabinoids act on the sameneurological
pathway that is disrupted in Parkinson’s disease. Involvement
of the endocannabinoid system in the regulation of motor
behavior, the localization of the cannabinoid receptors in
areas that control movement, and the effect of cannabi-
noids on motor activity indicate that cannabinoids can be
potentially used in the treatment of movement disorders.
Cannabinoid agonists and antagonists have been shown to
modulate the endocannabinoid system and modify motor
activity. Cannabinoid receptor antagonists appear to produce
antiparkinsonian effects while cannabinoid receptor agonists
exert a powerful motor inhibition and may be useful in
the treatment of motor complications. In addition, we have
assessed the role of the cannabinoid system and marijuana
constituents in neuroprotection as well as considered other
beneficial effects of marijuana. Marijuana has been shown
to improve nonmotor symptoms of PD such as depression,
pain, sleep, and anxiety. Moreover, components of cannabis
have been demonstrated to have neuroprotective effect due
to their anti-inflammatory, antioxidative, and antiexcitotoxic
properties. Due to combination of the above mentioned
beneficial effects, cannabis may provide a viable alternative
or addition to the current treatment of Parkinson’s disease.
However, there are concerns regarding the use of medical
marijuana including lack of standardization and regulation,
imprecise dosing, possible adverse effects, and medication
interactions. Further studies are needed to provide more
data on efficacy, safety, pharmacokinetics, and interactions of
cannabinoids.
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